Objective: The association of T2D and severe C-19 outcomes has been reported, but data are scarce on whether pre-existing CVD impacts C-19 outcomes in T2D patients. This study compared the clinical outcomes among C-19 patients with pre-existing T2D, T2D+CVD, or neither.

Methods: Retrospective study of claims and lab data to identify C-19 patients from 3/1/20 - 5/31/21 and stratify them by the presence of T2D and CVD. Outcomes included hospital/ICU admission and mortality. Propensity score matching and multivariable analyses were performed.

Results: After matching, 6,967 patients were identified for each group with a mean follow-up of 5.4 months; minimal residual baseline differences remained. Adjusted analyses (Table) show that C-19 patients with T2D+CVD or T2D only were more likely to be admitted to the hospital/ICU than those with neither (all p <0.01) , with the T2D+CVD group having greater odds. C-19 patients with T2D+CVD had a higher mortality risk compared to those with neither (p=0.02) . Among all T2D+CVD patients, acute respiratory distress syndrome (31%) , acute kidney disease (24%) , and ventilator use (8%) were observed.

Conclusion: Our study highlights the incrementally poorer outcomes associated with pre-existing T2D+CVD in C-19 patients and may suggest consideration of a more aggressive management approach in these patients with a less favorable prognosis.


C. Nguyen: Employee; HealthCore Inc. T. P. Power: None. R. Mehra: None. V. Willey: Employee; HealthCore Inc. C. Crowe: None. E. Kuti: Employee; Boehringer Ingelheim International GmbH. N. Narsipur: Employee; Boehringer Ingelheim International GmbH, Janssen Scientific Affairs, LLC. B. M. K. Donato: Employee; Boehringer Ingelheim International GmbH. R. S. Pepe: None. R. L. Djaraher: None. L. J. Seman: n/a. N. Graeter: Employee; Boehringer Ingelheim International GmbH.


Boehringer Ingelheim Pharmaceuticals Inc.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.